Drugs / RSV Polyclonal Immunoglobulin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT00001903 | Apr 1999 → May 2001 | respiratory syncytial virus infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RSV Polyclonal Immunoglobulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001903 ↗ |
| Known as | Respigam (Registered Trademark) | “RSV Polyclonal Immunoglobulin (Respigam® (Registered Trademark)) has been approved by the Food and Drug Administration” NCT00001903 ↗ |